{
    "root": "16e4a24f-b03c-4726-81d0-a6423f45ea5c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Phentermine Hydrochloride",
    "value": "20230927",
    "ingredients": [
        {
            "name": "PHENTERMINE HYDROCHLORIDE",
            "code": "0K2I505OTV",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50506"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        }
    ],
    "indications": {
        "text": "phentermine hydrochloride indicated short-term ( weeks ) adjunct regimen weight reduction based exercise , behavioral modification caloric restriction management exogenous obesity patients initial body mass index \u2265 30 kg/m2 , \u2265 27 kg/m2 presence risk factors ( e.g . , controlled hypertension , diabetes , hyperlipidemia ) . chart body mass index ( bmi ) based various heights weights . bmi calculated taking patient 's weight , kilograms ( kg ) , divided patient 's height , meters ( ) , squared . metric conversions follows : pounds \u00f7 2.2 = kg ; inches \u00d7 0.0254 = meters . body mass index ( bmi ) , kg/m2 limited usefulness agents class , including phentermine hydrochloride tablets , [ pharmacology ( 12.1 , 12.2 ) ] measured possible risk factors inherent described .",
        "doid_entities": [
            {
                "text": "obesity (DOID:9970)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9970"
            },
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            },
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 individualized obtain adequate response lowest effective dose . ( 2.1 ) \u2022 late evening avoided ( risk insomnia ) . ( 2.1 ) \u2022 phentermine hydrochloride tablets taken without food . ( 2.1 ) \u2022 limit 15 mg daily patients severe renal impairment ( egfr 15 29 ml/min/1.73 2 ) ( 2.2 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "phentermine hydrochloride tablets usp 37.5 mg ( equivalent 30 mg phentermine base ) white blue specks , oval shaped , scored one side debossed mp 273 side . ndc : 72162-1628-3 : 30 tablets bottle , plastic ndc : 72162-1628-1 : 100 tablets bottle , plastic ndc : 72162-1628-0 : 1000 tablets bottle , plastic store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) . [ usp controlled room temperature ] dispense tight , light-resistant container . keep reach children . repackaged/relabeled : bryant ranch prepack , inc. burbank , ca 91504",
    "adverseReactions": "\u2022history cardiovascular disease ( e.g . , coronary artery disease , stroke , arrhythmias , congestive heart failure , uncontrolled hypertension ) \u2022during within 14 days following monoamine oxidase inhibitors \u2022hyperthyroidism \u2022glaucoma \u2022agitated states \u2022history abuse \u2022pregnancy [ ( 8.1 ) ] \u2022nursing [ ( 8.3 ) ] \u2022known hypersensitivity , idiosyncrasy sympathomimetic amines",
    "indications_original": "Phentermine hydrochloride is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index \u2265 30 kg/m2, or \u2265 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia).\n                  Below is a chart of body mass index (BMI) based on various heights and weights.\n                  BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows: pounds \u00f7 2.2 = kg; inches \u00d7 0.0254 = meters.\n                  \n                     \n                     \n                        \n                           \n                              BODY MASS INDEX (BMI), kg/m2\n                              \n                           \n                        \n                        \n                           \n                              \n                           \n                        \n                     \n                  \n                  The limited usefulness of agents of this class, including phentermine hydrochloride tablets, [see Clinical Pharmacology (12.1, 12.2)\n                     ] should be measured against possible risk factors inherent in their use such as those described below.",
    "contraindications_original": "\u2022 Dosage should be individualized to obtain an adequate response with the lowest effective dose. (2.1) \u2022 Late evening administration should be avoided (risk of insomnia). (2.1) \u2022 Phentermine hydrochloride tablets can be taken with or without food. (2.1) \u2022 Limit the dosage to 15 mg daily for patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m 2 ) (2.2)",
    "warningsAndPrecautions_original": "Phentermine hydrochloride tablets USP 37.5 mg (equivalent to 30 mg phentermine base) are white with blue specks, oval shaped, scored on one side and debossed MP 273 on the other side.\n                  NDC: 72162-1628-3: 30 Tablets in a BOTTLE, PLASTIC\n                  NDC: 72162-1628-1: 100 Tablets in a BOTTLE, PLASTIC\n                  NDC: 72162-1628-0: 1000 Tablets in a BOTTLE, PLASTIC\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F).\n                  [See USP Controlled Room Temperature]\n                  DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.\n                  Keep out of the reach of children.\n                  Repackaged/Relabeled by:\n                  Bryant Ranch Prepack, Inc.\n                  Burbank, CA 91504",
    "adverseReactions_original": "\u2022History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension)\n                     \n                        \u2022During or within 14 days following the administration of monoamine oxidase inhibitors\n                     \n                        \u2022Hyperthyroidism\n                     \n                        \u2022Glaucoma\n                     \n                        \u2022Agitated states\n                     \n                        \u2022History of drug abuse\n                     \n                        \u2022Pregnancy [see Use in Specific Populations (8.1)\n                        ]\n                     \n                        \u2022Nursing [see Use in Specific Populations (8.3)\n                        ]\n                     \n                        \u2022Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines",
    "drug": [
        {
            "name": "Phentermine Hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50506"
        }
    ]
}